Vaxcyte
PCVX
88 hedge funds and large institutions have $1.2B invested in Vaxcyte in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
13% more capital invested
Capital invested by funds: $1.06B → $1.2B (+$140M)
3.82% more ownership
Funds ownership: 84.71% → 88.54% (+3.8%)
1% more funds holding
Funds holding: 87 → 88 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$28.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8M |
| 5 |
O
OrbiMed
New York
|
+$9.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$54.9M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$3.33M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$2.32M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.29M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$799K |
PCVX Hedge Fund Activity: Q1 2022 in Review
88 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2022, worth a combined $1.2B — up 13% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PCVX positions and 11 closed out — a net gain of 1 holder — while 36 added to existing stakes and 22 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $28.1M. The largest seller was Frazier Management, exiting entirely with an estimated $54.9M sold.
- 88 institutional investors held Vaxcyte (PCVX) as of Q1 2022, up from 87 in Q4 2021.
- Funds reported $1.2B of Vaxcyte stock for Q1 2022, up 13% quarter-over-quarter.
- 12 funds opened new Vaxcyte positions in Q1 2022 and 11 closed out, a net change of +1 holder.
- The largest Vaxcyte buyer in Q1 2022 was EcoR1 Capital, an estimated $28.1M added.
- The largest Vaxcyte seller in Q1 2022 was Frazier Management, an estimated $54.9M sold.
Based on aggregated 13F filings for Q1 2022.